Compounds > piracetam
Page last updated: 2024-11-02

piracetam and MS (Multiple Sclerosis)

piracetam has been researched along with MS (Multiple Sclerosis) in 11 studies

Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.

Research Excerpts

ExcerptRelevanceReference
"The literature provides contrasting results on the efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients with cerebellar signs."9.34Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study. ( Bergamaschi, R; de Sire, A; Gasperini, C; Messmer Uccelli, M; Mueller, M; Patti, F; Restivo, DA; Solaro, C; Stabile, MR, 2020)
"The aim of this study was to evaluate the activity measured by kinematic analysis, tolerability and efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients affected by cerebellar symptoms, in a randomized single-blind, placebo-controlled cross-over study."9.13Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. ( Abuarqub, S; Brichetto, G; Capello, E; Sanguineti, V; Solaro, C, 2008)
"Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A."6.77A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. ( Falah, M; Holbech, JV; Madsen, C; Sindrup, SH, 2012)
"Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS)."6.74Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. ( Bernardi, G; Buttari, F; Castelli, M; Centonze, D; Codecà, C; Fiore, S; Mataluni, G; Musella, A; Rossi, S, 2009)
"The literature provides contrasting results on the efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients with cerebellar signs."5.34Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study. ( Bergamaschi, R; de Sire, A; Gasperini, C; Messmer Uccelli, M; Mueller, M; Patti, F; Restivo, DA; Solaro, C; Stabile, MR, 2020)
"Levetiracetam was effective for reducing phasic spasticity but not tonic spasticity in this 12-patient case series."5.32Levetiracetam for phasic spasticity in multiple sclerosis. ( Frohman, E; Hawker, K; Racke, M, 2003)
"We studied efficacy and tolerability of the combined drug omaron (25 mg of cinnarizine and 400 mg of piracetam in one tablet) in patients with multiple sclerosis."5.14[Omaron in the complex treatment of patients with multiple sclerosis]. ( Batysheva, TT; Boĭko, AN; Kamchatnov, PR; Popova, NF; Riabukhina, OV; Zaĭtsev, KA, 2010)
"The aim of this study was to evaluate the activity measured by kinematic analysis, tolerability and efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients affected by cerebellar symptoms, in a randomized single-blind, placebo-controlled cross-over study."5.13Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. ( Abuarqub, S; Brichetto, G; Capello, E; Sanguineti, V; Solaro, C, 2008)
"A 44-year-old white woman with primary progressive MS receiving a multidrug of PO baclofen 75 mg/d, PO piracetam 3 g/d, and IV mitoxantrone 10 mg administered once a month presented to the Multiple Sclerosis Center, University of Catania, Catania, Italy."3.75Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis. ( Caruso, A; Neri, S; Patti, F; Vecchio, R, 2009)
"Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A."2.77A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. ( Falah, M; Holbech, JV; Madsen, C; Sindrup, SH, 2012)
"Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS)."2.74Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. ( Bernardi, G; Buttari, F; Castelli, M; Centonze, D; Codecà, C; Fiore, S; Mataluni, G; Musella, A; Rossi, S, 2009)
"Secondary paroxysmal dyskinesias (SPDs) are short, episodic, and recurrent movement disorders, classically related to multiple sclerosis (MS)."1.46Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients. ( Cárcamo-Rodríguez, C; Ciampi, E; Cruz, JP; Godoy-Santín, J; Juri, C; Uribe-San-Martín, R, 2017)
"Levetiracetam (LEV) is an established anticonvulsant with numerous mechanisms of action."1.38Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis. ( Ellrichmann, G; Faustmann, PM; Gold, R; Haghikia, A; Thöne, J, 2012)
"The incidence of seizures is generally accepted to be greater in patients with multiple sclerosis (MS) than in the general population, and rarely, MS can initially present as seizure."1.37Seizures as a manifestation of multiple sclerosis. ( Kendrick-Adey, AC; Sponsler, JL, 2011)
"Levetiracetam was effective for reducing phasic spasticity but not tonic spasticity in this 12-patient case series."1.32Levetiracetam for phasic spasticity in multiple sclerosis. ( Frohman, E; Hawker, K; Racke, M, 2003)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's5 (45.45)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Solaro, C2
de Sire, A1
Messmer Uccelli, M1
Mueller, M1
Bergamaschi, R1
Gasperini, C1
Restivo, DA1
Stabile, MR1
Patti, F2
Ciampi, E1
Uribe-San-Martín, R1
Godoy-Santín, J1
Cruz, JP1
Cárcamo-Rodríguez, C1
Juri, C1
Rossi, S1
Mataluni, G1
Codecà, C1
Fiore, S1
Buttari, F1
Musella, A1
Castelli, M1
Bernardi, G1
Centonze, D1
Caruso, A1
Vecchio, R1
Neri, S1
Popova, NF1
Kamchatnov, PR1
Riabukhina, OV1
Batysheva, TT1
Zaĭtsev, KA1
Boĭko, AN1
Sponsler, JL1
Kendrick-Adey, AC1
Falah, M1
Madsen, C1
Holbech, JV1
Sindrup, SH1
Thöne, J1
Ellrichmann, G1
Faustmann, PM1
Gold, R1
Haghikia, A1
Hawker, K1
Frohman, E1
Racke, M1
Striano, P1
Coppola, A1
Vacca, G1
Zara, F1
Brescia Morra, V1
Orefice, G1
Striano, S1
Brichetto, G1
Capello, E1
Abuarqub, S1
Sanguineti, V1

Trials

5 trials available for piracetam and MS (Multiple Sclerosis)

ArticleYear
Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study.
    European journal of neurology, 2020, Volume: 27, Issue:11

    Topics: Adult; Anticonvulsants; Cross-Over Studies; Double-Blind Method; Humans; Levetiracetam; Middle Aged;

2020
Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.
    European journal of neurology, 2009, Volume: 16, Issue:3

    Topics: Adult; Analgesics; Anticonvulsants; Depression; Disability Evaluation; Female; Humans; Levetiracetam

2009
[Omaron in the complex treatment of patients with multiple sclerosis].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:11 Pt 1

    Topics: Adult; Cinnarizine; Drug Combinations; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged;

2010
A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis.
    European journal of pain (London, England), 2012, Volume: 16, Issue:6

    Topics: Adult; Analgesics; Anticonvulsants; Chronic Pain; Cross-Over Studies; Female; Humans; Hyperalgesia;

2012
Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study.
    European journal of neurology, 2008, Volume: 15, Issue:6

    Topics: Biomechanical Phenomena; Cerebellum; Female; Humans; Levetiracetam; Male; Multiple Sclerosis; Nootro

2008

Other Studies

6 other studies available for piracetam and MS (Multiple Sclerosis)

ArticleYear
Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2017, Volume: 23, Issue:13

    Topics: Acetazolamide; Adult; Anticonvulsants; Cerebellum; Clonazepam; Dyskinesias; Dystonia; Female; Follow

2017
Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis.
    Clinical therapeutics, 2009, Volume: 31, Issue:3

    Topics: Administration, Oral; Adult; Baclofen; Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis;

2009
Seizures as a manifestation of multiple sclerosis.
    Epileptic disorders : international epilepsy journal with videotape, 2011, Volume: 13, Issue:4

    Topics: Adult; Anticonvulsants; Brain; Electroencephalography; Epilepsy, Tonic-Clonic; Female; Humans; Levet

2011
Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis.
    International immunopharmacology, 2012, Volume: 14, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Disease Models, Animal; Disease P

2012
Levetiracetam for phasic spasticity in multiple sclerosis.
    Archives of neurology, 2003, Volume: 60, Issue:12

    Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middl

2003
Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study.
    Journal of neurology, 2006, Volume: 253, Issue:6

    Topics: Activities of Daily Living; Adult; Anticonvulsants; Cerebellar Neoplasms; Disability Evaluation; Fem

2006